American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 353-365, August 2008

Fatigue in Patients Receiving Maintenance Dialysis: A Review of Definitions, Measures, and Contributing Factors

  • Manisha Jhamb, MD, MPH

      Affiliations

    • Western Pennsylvania Medical Center, Pittsburgh, PA
  • ,
  • Steven D. Weisbord, MD, MSc

      Affiliations

    • Renal Section and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA
    • Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, PA
  • ,
  • Jennifer L. Steel, PhD

      Affiliations

    • University of Pittsburgh School of Medicine, Liver Cancer Center, Department of Surgery, Starzl Transplantation Institute, Pittsburgh, PA
  • ,
  • Mark Unruh, MD, MSc

      Affiliations

    • Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, PA.
    • Corresponding Author InformationAddress correspondence to Mark Unruh, MD, MSc, University of Pittsburgh Medical Center, Renal-Electrolyte Division, 3550 Terrace St, A915 Scaife Hall, Pittsburgh, PA 15261.

Received 3 December 2007; accepted 7 May 2008. published online 24 June 2008.

Fatigue is a debilitating symptom or side effect experienced by many patients on long-term dialysis therapy. Fatigue has a considerable effect on patient health-related quality of life and is viewed as being more important than survival by some patients. Renal providers face many challenges when attempting to reduce fatigue in dialysis patients. The lack of a reliable, valid, and sensitive fatigue scale complicates the accurate identification of this symptom. Symptoms of daytime sleepiness and depression overlap with fatigue, making it difficult to target specific therapies. Moreover, many chronic health conditions common in the long-term dialysis population may lead to the development of fatigue and contribute to the day-to-day and diurnal variation in fatigue in patients. Key to improving the assessment and treatment of fatigue is improving our understanding of potential mediators, as well as potential therapies. Cytokines have emerged as an important mediator of fatigue and have been studied extensively in patients with cancer-related fatigue. In addition, although erythropoietin-stimulating agents have been shown to mitigate fatigue, the recent controversy regarding erythropoietin-stimulating agent dosing in patients with chronic kidney disease suggests that erythropoietin-stimulating agent therapy may not serve as the sole therapy to improve fatigue in this population. In conclusion, fatigue is an important and often underrecognized symptom in the dialysis population. Possible interventions for minimizing fatigue in patients on long-term dialysis therapy should aim at improving health care provider awareness, developing improved methods of measurement, understanding the pathogenesis better, and managing known contributing factors.

Index Words: Fatigue, end-stage renal disease, quality of life, psychometrics, cytokines, postdialysis fatigue

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2008.05.005 on June 23, 2008.

PII: S0272-6386(08)00878-0

doi:10.1053/j.ajkd.2008.05.005

American Journal of Kidney Diseases
Volume 52, Issue 2 , Pages 353-365, August 2008